Filing Analysis
Kewaunee Scientific Corporation held its Annual Meeting of Shareholders on August 26, 2026. Shareholders re-elected three Class I directors, ratified the appointment of Forvis Mazars, LLP as independent auditors for fiscal year 2027, and approved executive compensation on an advisory basis.
📋 Key Facts
- Annual Meeting of Shareholders held on August 26, 2026.
- Re-election of Class I directors: Thomas D. Hull III, David S. Rhind, and John D. Russell.
- Ratification of Forvis Mazars, LLP as independent auditors for fiscal year 2027.
- Advisory approval of named executive officer compensation for the fiscal year ended April 30, 2026.
Kewaunee Scientific Corporation filed an 8-K to announce the posting of an investor presentation and script related to its Annual Meeting of Shareholders. The filing is a routine disclosure under Item 7.01 to provide supplemental information to investors via the company's website.
📋 Key Facts
- The company held its Annual Meeting of Shareholders virtually on August 26, 2026.
- An investor presentation (Exhibit 99.1) and a related script (Exhibit 99.2) were released.
- The presentation includes non-GAAP financial information with reconciliations to GAAP measures provided.
- Information was furnished, not filed, pursuant to Item 7.01 of Form 8-K.
Kewaunee Scientific Corporation announced the scheduled release date for its first quarter fiscal 2027 earnings report. The announcement is a routine regulatory update regarding upcoming financial disclosures.
📋 Key Facts
- First quarter fiscal 2027 earnings release is scheduled for September 9, 2026.
- The announcement was made on August 25, 2026.
- The company is listed on the Nasdaq Global Market under the ticker KEQU.
Kewaunee Scientific Corporation has filed an 8-K to announce its financial results for the fourth quarter and fiscal year ended April 30, 2026. The filing serves as a formal notification of the release of earnings data via press release.
📋 Key Facts
- Reporting period: Fourth quarter and fiscal year ended April 30, 2026.
- Announcement date: June 23, 2026.
- The filing includes a press release as Exhibit 99.1 containing the financial results.
Kewaunee Scientific Corporation announced that it intends to release its financial results for the fourth quarter and fiscal year ended April 30, 2026, on June 23, 2026.
📋 Key Facts
- Fiscal year ended April 30, 2026
- Earnings release date scheduled for June 23, 2026
- Filing date: June 10, 2026
Kewaunee Scientific Corporation announced its financial results for the third quarter of fiscal year 2026 via a press release on March 11, 2026.
📋 Key Facts
- The company reported financial results for the third quarter of fiscal year 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was furnished as Exhibit 99.1.
Kewaunee Scientific Corporation (KEQU) announced that it will release its financial results for the third quarter of fiscal year 2026 on March 11, 2026.
📋 Key Facts
- The company plans to release Q3 fiscal 2026 earnings on March 11, 2026.
- The announcement was made via a press release on February 25, 2026.
- The filing includes Exhibit 99.1, the press release detailing the announcement.
Kewaunee Scientific Corporation has filed an 8-K to announce its financial results for the second quarter of fiscal year 2026. The filing serves as a formal announcement of the earnings release issued on December 10, 2025.
📋 Key Facts
- Company announced Q2 FY2026 financial results on December 10, 2025.
- The filing includes Exhibit 99.1 containing the press release of the earnings results.
- Signed by Donald T. Gardner III, Vice President, Finance and CFO.
Kewaunee Scientific Corporation has entered into a First Amendment to its Loan Agreement with PNC Bank to facilitate the full repayment of $23.0 million in subordinated seller notes related to the Nu Aire, Inc. acquisition. The restructuring includes an additional $10.0 million term loan and the use of available revolving credit facilities to satisfy these obligations.
🚩 Red Flags
- Increased debt load via a new $10.0 million term loan to pay off existing subordinated debt.
- The repayment of seller notes (related to the Nu Aire acquisition) suggests a need to clean up the balance sheet or satisfy specific terms related to an acquisition.
📋 Key Facts
- Entered into First Amendment to Loan Agreement with PNC Bank on December 4, 2025.
- Repaid $23.0 million in outstanding principal plus accrued interest (8% per annum) of subordinated seller notes.
- Obtained an additional $10.0 million term loan to fund part of the repayment.
- Utilized available funds from existing revolving line of credit to complete the repayment.
- The Seller Notes were originally issued in November 2024 and were scheduled to mature on November 1, 2027.
Kewaunee Scientific Corporation announced the upcoming release date for its second quarter fiscal 2026 earnings report. The company plans to publish these results on December 10, 2025.
📋 Key Facts
- Earnings Release Date: December 10, 2025
- Reporting Period: Second Quarter Fiscal 2026
- Filing Date: November 26, 2025
Kewaunee Scientific Corporation announced the appointment of J. Jette Campbell to its Board of Directors and Audit Committee, effective September 10, 2025. The company also amended its bylaws to adjust the permitted number of directors on the Board.
🚩 Red Flags
- The appointment of a specialist in 'financial restructuring' and 'crisis management' can sometimes signal underlying operational or financial distress, though not explicitly stated here.
📋 Key Facts
- J. Jette Campbell appointed as a Class II director, term expiring in 2027.
- Mr. Campbell will serve on the Audit Committee and meets Nasdaq independence/financial literacy requirements.
- Bylaws amended to set the Board size between five and nine directors.
- Mr. Campbell brings extensive experience in financial restructuring, crisis management, and CFO roles at PepsiCo and DuPont joint ventures.
Kewaunee Scientific Corporation has filed an 8-K to furnish its press release announcing financial results for the first quarter of fiscal year 2026.
📋 Key Facts
- The filing was made on September 10, 2025.
- The report pertains to the Q1 FY2026 financial results.
- Financial results were announced via a press release dated September 10, 2025 (Exhibit 99.1).
Kewaunee Scientific Corporation held its Annual Meeting of Shareholders on August 27, 2025. The filing reports the results of shareholder votes regarding director re-elections, auditor ratification, executive compensation approval, and the frequency of future advisory compensation votes.
📋 Key Facts
- Annual Meeting held on August 27, 2025.
- Margaret B. Pyle was re-elected as Class III director (1,633,067 votes in favor).
- Donald F. Shaw was re-elected as Class III director (1,730,171 votes in favor).
- Ratification of Forvis Mazars, LLP as independent auditors for fiscal year 2026.
- Named executive officer compensation approved on an advisory basis.
- Shareholders voted to maintain an annual frequency for the advisory vote on executive compensation.
Kewaunee Scientific Corporation filed an 8-K to announce the posting of an investor presentation and script related to its Annual Meeting of Shareholders held on August 27, 2025. The filing includes non-GAAP financial information reconciled to GAAP measures.
📋 Key Facts
- The company conducted a virtual Annual Meeting of Shareholders on August 27, 2025.
- An investor presentation (Exhibit 99.1) and script (Exhibit 99.2) were released via the company's website.
- The filing includes non-GAAP financial information with reconciliations to GAAP measures provided in the exhibits.
Kewaunee Scientific Corporation announced its intent to release first quarter fiscal 2026 earnings on September 10, 2025.
📋 Key Facts
- Earnings release date for Q1 Fiscal 2026 is scheduled for September 10, 2025.
- The announcement was made via an 8-K filing dated August 27, 2025.
Kewaunee Scientific Corporation has filed an 8-K to furnish its press release announcing financial results for the fourth quarter and fiscal year ended April 30, 2025.
📋 Key Facts
- Report date: June 25, 2025
- Reporting period: Fourth quarter and fiscal year ended April 30, 2025
- The filing is intended to satisfy the requirements of Item 2.02 regarding results of operations and financial condition.
- Financial data is contained in Exhibit 99.1 (Press Release).
Kewaunee Scientific Corporation announced the upcoming release of its fourth quarter and fiscal year 2025 financial results. The earnings announcement is scheduled for June 25, 2025.
📋 Key Facts
- Company plans to release Q4 and full fiscal year results for the period ended April 30, 2025.
- Earnings release date set for June 25, 2025.
- Filing includes a press release dated June 11, 2025, as Exhibit 99.1.
Kewaunee Scientific Corporation has amended its existing share repurchase program to authorize the purchase of up to an additional 100,000 shares of common stock. This amendment expands upon a program originally approved on August 31, 2023.
📋 Key Facts
- Board authorized repurchase of up to an additional 100,000 shares of common stock.
- The original program was approved on August 31, 2023, and became effective September 1, 2023.
- Prior to this amendment, 11,176 shares remained authorized for repurchase under the existing program.
- Repurchases will be made at management's discretion based on capital needs and market conditions.
- The program has no specified expiration date.
Kewaunee Scientific Corporation filed an 8-K to announce its financial results for the third quarter of fiscal year 2025. The filing serves as a formal notification that a press release containing these results was issued on March 12, 2025.
📋 Key Facts
- The company announced Q3 FY2025 financial results on March 12, 2025.
- Financial results were released via press release (Exhibit 99.1).
- Report filed by Donald T. Gardner III, CFO.
Kewaunee Scientific Corporation announced the scheduled date for its third quarter fiscal 2025 earnings release. The company plans to publish these results on March 12, 2025.
📋 Key Facts
- Earnings release date: March 12, 2025
- Reporting period: Third Quarter Fiscal 2025
- Filing date: February 26, 2025
Kewaunee Scientific Corporation has completed the acquisition of Nu Aire, Inc. for an aggregate purchase price of $55 million. The filing provides the required audited financial statements and pro forma information following the transaction closed on November 1, 2024.
🚩 Red Flags
- Significant increase in leverage: The company took on $35M in bank debt plus $23M in seller notes ($58M total) to fund a $55M acquisition, significantly altering the capital structure.
- Subordinated debt obligation: The $23M in seller notes is subordinated and carries an 8% interest rate, creating a significant cash outflow requirement over the next three years.
📋 Key Facts
- Acquisition of Nu Aire, Inc. for a total consideration of $55,000,000 (subject to customary adjustments).
- Financing includes a $20,000,000 senior secured revolving credit facility with PNC Bank and a $15,000,000 term loan.
- Issued $23,000,000 in subordinated seller notes to the sellers at an 8% annual interest rate, maturing on November 1, 2027.
- The filing includes audited financial statements for Nu Aire as of fiscal year ended September 30, 2024.
- Pro forma financial information is provided to illustrate the impact of the acquisition and new debt on the combined company's balance sheet and operations.
Kewaunee Scientific Corporation filed an 8-K to announce its financial results for the second quarter of fiscal year 2025. The filing serves as a formal announcement and provides access to the press release containing the detailed earnings data.
📋 Key Facts
- Reported date: December 11, 2024
- Subject matter: Financial results for Q2 fiscal year 2025
- Exhibits include a press release dated December 11, 2024 (Exhibit 99.1)
Kewaunee Scientific Corporation announced its intention to release second quarter fiscal 2025 earnings on December 11, 2024.
📋 Key Facts
- Earnings release date: December 11, 2024.
- Reporting period: Second quarter fiscal 2025.
- Filing date: November 27, 2024.
Kewaunee Scientific Corporation completed the acquisition of Nu Aire, Inc. for an aggregate purchase price of $55 million on November 1, 2024. The transaction was funded through a combination of cash ($32M) and subordinated seller notes ($23M), with the cash portion financed via new credit facilities from PNC Bank.
🚩 Red Flags
- Significant increase in leverage: The company took on $35M in new debt (Revolving + Term Loan) to fund the acquisition.
- Equity kicker/Death spiral risk: Seller Notes include a security agreement allowing Sellers to convert debt into common stock upon an Event of Default, calculated based on VWAP or closing price.
- Subordinated debt: $23M in seller notes are subordinate to PNC Bank's claims.
- Restrictive covenants: New loan agreements include strict financial ratios (Senior Debt/EBITDA < 2.50x and Fixed Charge Coverage > 1.20x).
📋 Key Facts
- Acquisition price: $55,000,000 aggregate (subject to customary adjustments).
- Funding structure: $32,000,000 in cash and $23,000,000 in subordinated seller notes.
- New debt: Entered into a Loan Agreement with PNC Bank including a $20M revolving credit facility and a $15M term loan maturing November 1, 2029.
- Seller Notes terms: 8% per annum interest rate; matures on the 3rd anniversary (November 1, 2027).
- Management change: William F. Peters to serve as President of Nu Aire and Vice President of Kewaunee Scientific through at least Dec 31, 2026.
- $1,000,000 of the purchase price is held in a working capital escrow for post-closing true-ups.
Kewaunee Scientific Corporation filed an 8-K to announce its financial results for the first quarter of fiscal year 2025. The filing serves as a formal notice that a press release containing these results was issued on September 11, 2024.
📋 Key Facts
- The company announced Q1 FY2025 financial results on September 11, 2024.
- Financial results were released via press release (Exhibit 99.1).
- The filing was signed by Donald T. Gardner III, CFO.
Kewaunee Scientific Corporation held its Annual Meeting of Shareholders on August 28, 2024. The filing reports the results of shareholder votes regarding director re-election, auditor ratification, and executive compensation.
📋 Key Facts
- Annual Meeting of Shareholders held on August 28, 2024.
- Keith M. Gehl was re-elected as a Class II director for a three-year term with 1,404,874 votes in favor.
- Ratification of Forvis Mazars, LLP as independent auditors for fiscal year 2025 received 2,414,204 votes in favor.
- Compensation of named executive officers was approved on an advisory basis with 1,440,693 votes in favor.
Kewaunee Scientific Corporation filed an 8-K to announce the posting of an investor presentation and script related to its Annual Meeting of Shareholders held on August 28, 2024. The filing includes non-GAAP financial information which is reconciled to GAAP measures in the attached exhibits.
📋 Key Facts
- The company held its Annual Meeting of Shareholders virtually on August 28, 2024.
- An investor presentation (Exhibit 99.1) and script (Exhibit 99.2) were released via the company's website.
- The filing includes non-GAAP financial information with reconciliations to GAAP measures provided in the exhibits.
Kewaunee Scientific Corporation announced the upcoming release of its first quarter fiscal 2025 earnings, scheduled for September 11, 2024.
📋 Key Facts
- Earnings release date: September 11, 2024
- Reporting period: First Quarter Fiscal 2025
- Filing date: August 28, 2024
Kewaunee Scientific Corporation has filed an 8-K to furnish its press release announcing financial results for the fourth quarter and fiscal year ended April 30, 2024.
📋 Key Facts
- The filing reports on the fiscal year ending April 30, 2024.
- Financial results were announced via a press release dated June 26, 2024.
- The report includes Exhibit 99.1 containing the full press release.
Kewaunee Scientific Corporation announced the upcoming release of its fourth quarter and fiscal year 2024 financial results. The earnings announcement is scheduled for June 26, 2024.
📋 Key Facts
- Company plans to release Q4 and full fiscal year results ended April 30, 2024.
- Earnings release date set for June 26, 2024.
- Filing includes a press release as Exhibit 99.1.
Kewaunee Scientific Corporation announced the termination of its pension plan effective April 30, 2024. The company has transferred approximately $17.7 million in pension obligations via group annuity contracts to settle remaining liabilities.
🚩 Red Flags
- None identified; this appears to be a standard de-risking/pension wind-down strategy.
📋 Key Facts
- Pension plan termination effective date: April 30, 2024.
- Transferred approximately $17.7 million of pension obligations through the purchase of group annuity contracts.
- Company contributed approximately $0.3 million in cash to fully fund remaining defined benefit liabilities.
- Plan participant benefits remain unchanged as a result of this transaction.
Kewaunee Scientific Corporation entered into a retention bonus agreement with its President and CEO, Thomas D. Hull III, on March 18, 2024. The agreement is designed to incentivize the CEO's continued employment through at least March 2027.
🚩 Red Flags
- Retention bonuses can sometimes signal management instability or high turnover risk, though the clawback provision mitigates this specific risk.
📋 Key Facts
- Effective Date of Agreement: March 18, 2024
- Recipient: Thomas D. Hull III (President and CEO)
- Bonus Amount: $250,000 cash retention bonus
- Clawback Provision: 100% reimbursement required if CEO resigns voluntarily or is terminated for Cause before March 18, 2027 (36 months from Effective Date).
Kewaunee Scientific Corporation filed an 8-K to announce its financial results for the third quarter of fiscal year 2024. The filing serves as a formal notice that a press release containing these results was issued on March 6, 2024.
📋 Key Facts
- Company announced Q3 FY2024 financial results on March 6, 2024.
- The announcement was made via a press release furnished as Exhibit 99.1.
- Filing includes the standard cover page and interactive data files.
Kewaunee Scientific Corporation announced the scheduled date for its third quarter fiscal 2024 earnings release. The company expects to publish results on March 6, 2024.
📋 Key Facts
- Earnings release date set for March 6, 2024.
- The announcement pertains to the third quarter of fiscal year 2024.